Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) closed the day trading at $260.51 down -0.20% from the previous closing price of $261.02. In other words, the price has decreased by -$0.20 from its previous closing price. On the day, 1.04 million shares were traded. ALNY stock price reached its highest trading level at $263.71 during the session, while it also had its lowest trading level at $258.795.
Ratios:
For a better understanding of ALNY, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.90 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 257.80. For the most recent quarter (mrq), Quick Ratio is recorded 3.07 and its Current Ratio is at 3.17.
On December 08, 2023, Wells Fargo started tracking the stock assigning a Equal Weight rating and target price of $171.Wells Fargo initiated its Equal Weight rating on December 08, 2023, with a $171 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 11 ’24 when Greenstreet Yvonne sold 7,093 shares for $261.00 per share. The transaction valued at 1,851,273 led to the insider holds 73,441 shares of the business.
SCHULMAN AMY W sold 8,500 shares of ALNY for $2,040,000 on Jun 25 ’24. The Director now owns 8,436 shares after completing the transaction at $240.00 per share. On Jun 25 ’24, another insider, Greenstreet Yvonne, who serves as the Chief Executive Officer of the company, sold 8,301 shares for $230.99 each. As a result, the insider received 1,917,475 and left with 80,534 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALNY now has a Market Capitalization of 32952432640 and an Enterprise Value of 33265389568. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.45. Its current Enterprise Value per Revenue stands at 16.605 whereas that against EBITDA is -272.005.
Stock Price History:
Over the past 52 weeks, ALNY has reached a high of $262.82, while it has fallen to a 52-week low of $141.98. The 50-Day Moving Average of the stock is 47.33%, while the 200-Day Moving Average is calculated to be 54.39%.
Shares Statistics:
Over the past 3-months, ALNY traded about 961.32K shares per day on average, while over the past 10 days, ALNY traded about 1263660 shares per day. A total of 125.79M shares are outstanding, with a floating share count of 125.76M. Insiders hold about 0.58% of the company’s shares, while institutions hold 90.76% stake in the company. Shares short for ALNY as of 1719532800 were 3676470 with a Short Ratio of 3.82, compared to 1717113600 on 2478157. Therefore, it implies a Short% of Shares Outstanding of 3676470 and a Short% of Float of 3.35.
Earnings Estimates
The market rating of Alnylam Pharmaceuticals Inc (ALNY) is currently shaped by the ongoing analysis conducted by 20.0 analysts closely monitoring its performance.On average, analysts expect EPS of -$1.09 for the current quarter, with a high estimate of -$0.36 and a low estimate of -$1.57, while EPS last year was -$2.21. The consensus estimate for the next quarter is -$1.05, with high estimates of -$0.31 and low estimates of -$1.69.
Analysts are recommending an EPS of between -$1.07 and -$5.68 for the fiscal current year, implying an average EPS of -$3.55. EPS for the following year is -$1.64, with 24.0 analysts recommending between $2.31 and -$3.78.
Revenue Estimates
23 analysts predict $445.98M in revenue for the current quarter. It ranges from a high estimate of $492M to a low estimate of $415M. As of the current estimate, Alnylam Pharmaceuticals Inc’s year-ago sales were $318.75MFor the next quarter, 23 analysts are estimating revenue of $459.85M. There is a high estimate of $495.5M for the next quarter, whereas the lowest estimate is $441M.
A total of 29 analysts have provided revenue estimates for ALNY’s current fiscal year. The highest revenue estimate was $2B, while the lowest revenue estimate was $1.73B, resulting in an average revenue estimate of $1.88B. In the same quarter a year ago, actual revenue was $1.83BBased on 29 analysts’ estimates, the company’s revenue will be $2.32B in the next fiscal year. The high estimate is $2.97B and the low estimate is $1.48B.
